Barely Significant
← all excerpts

Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.

Ther Adv Med Oncol · 2025 · PMC11907608 · PMID 40093981

Europe PMCDOI
1
hedged sentence
0.0670
closest p · 1.3× alpha
0.0670
boldest claim

The sentences

marginally non-significantp = 0.067so close (0.05 < p ≤ 0.1)
Furthermore, SG showed a longer, but marginally non-significant DOR compared to TPC among prior CDK4/6i-treated (HR, 0.58 (95% CI: 0.32–1.04); p = 0.067) and fast-progressors population (HR, 0.68 (95% CI: 0.32–1.46); p = 0.324) due to lower number of patients with complete response or partial response in both trials ( n = 155, 116 and 76 for overall, prior CDK4/6i-treated, and fast-progressors population, respectively; Figure 6 ).

also in 625 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.